Co-Diagnostics: Q3 Earnings Insights

Shares of Co-Diagnostics CODX decreased 22.88% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 630.00% over the past year to $0.53, which missed the estimate of $0.63.

Revenue of $21,819,000 up by 52559.65% year over year, which missed the estimate of $32,790,000.

Outlook

Co-Diagnostics hasn't issued any earnings guidance for the time being.

Co-Diagnostics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 16, 2020

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1775/38520

Price Action

52-week high: $30.99

52-week low: $0.85

Price action over last quarter: down 31.55%

Company Overview

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.